Advertisement

Advertisement

CLNN Stock Latest News

Clene, Lovesac, HDFC Bank, State Street, Vor Shock

Weekend UpdatesClene, Lovesac, HDFC Bank, State Street, Vor Shock

Surf Air, Cytokinetics, ASE, Itau, Clene Insider Shake-Up

PremiumWeekend Updates

Surf Air, Cytokinetics, ASE, Itau, Clene Insider Shake-Up

7d ago

Insiders Cash Out: Cytokinetics, Itau, ASE, Clene, Black Stone

PremiumWeekend Updates

Insiders Cash Out: Cytokinetics, Itau, ASE, Clene, Black Stone

14d ago

Clene Secures Third-Year NIH Subaward for ALS Program

PremiumCompany Announcements

Clene Secures Third-Year NIH Subaward for ALS Program

1M ago

Clene reports FY25 EPS ($2.65), consensus ($2.35)

PremiumThe Fly

Clene reports FY25 EPS ($2.65), consensus ($2.35)

1M ago

Clene outlines 2026 regulatory milestones and ALS strategy

PremiumCompany AnnouncementsClene outlines 2026 regulatory milestones and ALS strategy

2M ago

Clene issues letter to shareholders on CNM-Au8 2026 catalysts

The Fly

Clene issues letter to shareholders on CNM-Au8 2026 catalysts

2M ago

Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed

Weekend Updates

Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed

3M ago

Clene Announces Multi-Tranche Financing to Extend Cash Runway

PremiumCompany Announcements

Clene Announces Multi-Tranche Financing to Extend Cash Runway

3M ago

Clene Advances CNM-Au8 ALS Program with FDA Meeting

PremiumCompany Announcements

Clene Advances CNM-Au8 ALS Program with FDA Meeting

3M ago

Clene announces additional CNM-Au8 biomarker data for potential NDA filing

PremiumThe Fly

Clene announces additional CNM-Au8 biomarker data for potential NDA filing

3M ago

Clene announces over $28M registered direct offering

PremiumThe Fly

Clene announces over $28M registered direct offering

4M ago

Clene price target raised to $30 from $20 at Maxim

PremiumThe FlyClene price target raised to $30 from $20 at Maxim

5M ago

Clene’s CNM-Au8 Shows Promise in ALS Treatment, Projecting Significant Stock Upside

Ratings

Clene’s CNM-Au8 Shows Promise in ALS Treatment, Projecting Significant Stock Upside

5M ago

Clene Updates on CNM-Au8® ALS Program

Company Announcements

Clene Updates on CNM-Au8® ALS Program

5M ago

Clene Announces Positive Biomarker Results for CNM-Au8

PremiumCompany Announcements

Clene Announces Positive Biomarker Results for CNM-Au8

5M ago

Clene announces significant reductions in NfL, GFAP when treated with CNM-Au8

PremiumThe Fly

Clene announces significant reductions in NfL, GFAP when treated with CNM-Au8

5M ago

Clene Inc.: Promising Future with CNM-Au8 Advancements and Strategic Financial Management

PremiumRatings

Clene Inc.: Promising Future with CNM-Au8 Advancements and Strategic Financial Management

5M ago

Clene Inc. Reports Continued Financial Losses in Q3 2025

PremiumCompany Announcements

Clene Inc. Reports Continued Financial Losses in Q3 2025

5M ago

Clene reports Q3 EPS (85c), consensus (56c)

PremiumThe FlyClene reports Q3 EPS (85c), consensus (56c)

5M ago

Clene sees cash runway into 2Q26

The Fly

Clene sees cash runway into 2Q26

5M ago

Buy Rating for Clene’s CNM-Au8 Driven by Promising ALS Treatment Potential and Market Interest

Ratings

Buy Rating for Clene’s CNM-Au8 Driven by Promising ALS Treatment Potential and Market Interest

6M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >